Epizyme President of Research and Chief Scientific Officer Named AAAS Fellow
November 21 2016 - 11:00AM
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical
company creating novel epigenetic therapies, today announced that
President of Research and Chief Scientific Officer, Robert A.
Copeland, Ph.D., has been named a fellow of the American
Association for the Advancement of Science (AAAS), the world’s
largest general scientific society. Fellows are elected by the
association’s membership in recognition of their efforts toward
advancing science applications that are deemed scientifically or
socially distinguished. Dr. Copeland will be recognized at a
ceremony on February 18 at the 2017 AAAS Annual Meeting in Boston,
Mass.
“I am honored to be recognized by AAAS and join the ranks of
such an accomplished group of scientists,” said Robert A. Copeland,
Ph.D. “I am extremely fortunate to have worked with many talented
researchers and colleagues in my years at Epizyme who have
contributed greatly to the work recognized by AAAS and I look
forward to our continued leadership in the field.”
Dr. Copeland was chosen by the Section on Biological Sciences
for his insights contributing to small molecule therapeutics and
the discovery that a heterozygous enzymatic activity between a
wild-type and mutant enzyme contributes to oncogenesis. During his
career, he has contributed to drug discovery and development
efforts across a wide range of therapeutic areas leading to three
approved drugs and nearly 20 candidates entering human clinical
trials, has contributed more than 200 publications in the
scientific literature, holds 13 issued U.S. patents and has
authored 5 books in the areas of protein science and enzymology.
Under Dr. Copeland’s leadership, Epizyme discovered a number of
novel epigenetic targets and developed three first-of-their-kind
potential new medicines that have advanced into the clinic,
including tazemetostat, an EZH2 inhibitor being evaluated across
multiple cancer indications.
“Bob’s achievements have contributed greatly to the scientific
community’s understanding of the epigenetic mechanisms driving
cancer development,” said Robert Bazemore, President and CEO,
Epizyme. “His insights and leadership have helped Epizyme pioneer
the field of epigenetics and the discovery and development of
tazemetostat, the most advanced EZH2 inhibitor in the clinic
today.”
The full list of awardees may be found in the November 25 issue
of the journal, Science.
About Epizyme, Inc. Epizyme, Inc. is a clinical
stage biopharmaceutical company creating novel epigenetic
therapeutics for cancer patients. Epizyme has built a proprietary
product platform that the Company uses to create small molecule
inhibitors of a 96-member class of enzymes known as histone
methyltransferases, or HMTs. HMTs are part of the system of gene
regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the
activity of HMTs, making them oncogenic (cancer-causing). By
focusing on the genetic drivers of cancers, Epizyme's targeted
science seeks to match the right medicines with the right patients.
For more information, visit www.epizyme.com.
About AAASThe American Association for the
Advancement of Science (AAAS) is the world’s largest general
scientific society and publisher of the journal Science
(www.sciencemag.org) as well as Science Translational Medicine,
Science Signaling, a digital, open-access journal, Science
Advances, Science Immunology, and Science Robotics. AAAS was
founded in 1848 and includes nearly 250 affiliated societies and
academies of science, serving 10 million individuals. Science has
the largest paid circulation of any peer-reviewed general science
journal in the world. The non-profit AAAS (www.aaas.org) is open to
all and fulfills its mission to “advance science and serve society”
through initiatives in science policy, international programs,
science education, public engagement, and more. For the latest
research news, log onto EurekAlert! (www.eurekalert.org), the
premier science-news Web site, a service of AAAS. See
www.aaas.org.
Epizyme Contact:
Julie DiCarlo, (617) 306-5823
jdicarlo@epizyme.com
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Apr 2023 to Apr 2024